Glumetza 1,000mg will be introduced to health-care professionals throughout the country by Biovail Pharmaceuticals Canada (BPC), the company’s Canadian sales and marketing division.
Scott Smith, vice-president and general manager of BPC, said: “Clinical data exists to show that reducing the frequency of daily dosing of oral diabetes medication can cause an improvement in patient compliance and metabolic control. The launch of Glumetza 1,000mg is an important development for the majority of patients who require more than 500mg of metformin daily as part of their treatment.”